# A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

> **NCT06820463** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 390 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Telisotuzumab Adizutecan
- **DRUG:** Fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Bevacizumab
- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT06820463
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-24
- **Primary completion:** 2028-03
- **Final completion:** 2028-04
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06820463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06820463, "A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06820463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*